About Us

Established in 1995 Ind-Swift has fast evolved towards a business model that is focused on deep-rooted domestic presence and leveraged on high-value mature regulated markets along with considerable growth in emerging markets:

» Ind-Swift Laboratories Ltd. (Manufacturer of APIs)
» Ind-Swift Laboratories Inc. (US Subsidiary)
» Ind Swift Menthol

With manufacturing sites at 6 different locations across India and an independent State-of-the-Art R&D Centre, the Group has embarked upon a journey to establish itself as reliable partner in the Global Pharmaceutical Industry. In house capabilities for Development of APIs, Finished Dosage forms, Non-Infringing Process & World Class facilities for Contract Manufacturing are the inherent strengths.

Vision & Value

Consistent Profitable Performance
Commitment to maximize the wealth of our shareholders and catering to the interests of our customers and employees.

Innovation to Nurture Good Partnerships with Customers
Develop therapies and processes and provide services of the highest value to nurture good partnerships with customers.

Responsibility towards Environment, Safety and Health
Nurturing the undying spirit for researching active substances to combat disease, protect the environments we inhabit, and the Society we serve.

Valuing the Ability to Excel, Integrity, Knowledge, Skill, Diversity and Team work in Employees
Treat everyone fairly and with respect to create an environment of mutual respect, encouragement and teamwork.

The Strength to live a Dream
Ind-Swift today is a well balanced, professionally managed, globally competitive organization and will continue to profitably serve all stakeholders including patients, healthcare professionals, employees, business associates and shareholders.

The Company is stronger today than it was at any time in the past, and we are confident that it has great potential for the future too. We shall continue to foster value creation with renewed commitment and focus on long-term success to benefit our customers, employees and investors.

Share: